HER2 imaging by SPECT-CT using 111In radiolabeled pertuzumab-fab DOTAGA-conjugate: A proof of concept study in a preclinical model of breast cancer - Université de Bourgogne Accéder directement au contenu
Poster De Conférence Année : 2017

HER2 imaging by SPECT-CT using 111In radiolabeled pertuzumab-fab DOTAGA-conjugate: A proof of concept study in a preclinical model of breast cancer

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-01753105 , version 1 (29-03-2018)

Identifiants

  • HAL Id : hal-01753105 , version 1

Citer

Alexandra Oudot, Pierre-Simon Bellaye, Jean-Marc Vrigneaud, Olivier Raguin, Claire Bernhard, et al.. HER2 imaging by SPECT-CT using 111In radiolabeled pertuzumab-fab DOTAGA-conjugate: A proof of concept study in a preclinical model of breast cancer . 2017 San Antonio Breast Cancer Symposium, Dec 2017, San Antonio, Texas, United States. , Cancer Research, 78 (4), pp.Meeting Abstract: P5-01-03, 2018. ⟨hal-01753105⟩
169 Consultations
0 Téléchargements

Partager

Gmail Mastodon Facebook X LinkedIn More